1. Scrip

J&J/Protagonist’s JNJ-2113 Advancing To Pivotal Psoriasis Trial But Efficacy Questions Remain

 
• By Ayisha Sharma

The partners’ orally administered IL-23R inhibitor met all primary and secondary endpoints in a Phase IIb plaque psoriasis trial, justifying advancement to Phase III even though its efficacy fell short of available injectables according to cross-trial comparisons.    

Graphic of two people pushing a cube and a cylinder
Cross-Trial Comparisons Presented Some Concerning Caveats • Source: Shutterstock
Key Takeaways:

  • JNJ-2113 attained a 78.6% PASI75 response at its highest dose in the Phase IIb trial.

  • Protagonist’s stock price dropped after selected data were leaked early.

  • Analysts remained optimistic, noting the drug’s efficacy compared favorably to other oral assets.

Johnson & Johnson/Protagonist Therapeutics, Inc

Topline data from the Phase IIb FRONTIER 1 trial were presented at the World Congress of Dermatology annual meeting in Singapore

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D